Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The impact of direct oral anticoagulants (DOACs) on laboratory assays used for thrombophilia testing (e.g., antithrombin, protein S, protein C, lupus anticoagulant and activated protein-C resistance) is a well-known issue and may cause false-positive and -negative results. Therefore, the correct interpretation of tests that are performed in patients taking DOACs is mandatory to prevent misclassification and the subsequent clinical consequences. We aimed at evaluating the efficiency of a new and simple procedure (DOAC-Stop®; Haematex Research, Hornsby, Australia) to overcome the effect of all DOACs in real-life settings and to assess the percentage of erroneous results due to the presence of DOACs on thrombophilia screening tests. For this purpose, 135 DOAC-treated patients (38 apixaban, 40 dabigatran, 15 edoxaban, and 42 rivaroxaban) and 20 control patients were enrolled. A significant drop in apixaban, dabigatran, edoxaban, and rivaroxaban plasma concentrations following the DOAC-Stop® treatment was observed (74.8-8.2 ng/mL [ < 0.0001], 95.9-4.7 ng/mL [ < 0.0001], 102.1-8.8 ng/mL [ = 0.001], and 111.3-7.0 ng/mL [ < 0.0001], respectively). The DOAC-Stop® treatment was mostly effective to overcome the effect of DOACs on PTT-LA, dilute Russell's viper venom time (dRVVT) screen, and dRVVT confirm tests. Using our procedures, false-positive results due to DOACs were observed only with lupus anticoagulant tests (up to 75%) and fell to zero after the DOAC-Stop® procedure, regardless of the DOAC considered. In conclusion, the DOAC-Stop® adsorbent procedure appeared to be an effective and simple way to overcome the interference of DOAC on coagulation tests and should facilitate the interpretation of thrombophilia screening tests in patients taking DOACs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524876 | PMC |
| http://dx.doi.org/10.1055/s-0038-1657785 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population-How to Overcome the Challenges of Geriatric Syndromes.
J Clin Med
June 2025
Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Because the number of elderly people is increasing worldwide, and the prevalence of cardiovascular risk factors and cardiovascular diseases increase with age, in current clinical practice we are faced with a large number of geriatric patients requiring oral anticoagulant treatment. Our review highlights some of the particularities of using direct oral anticoagulants (DOACs) in the geriatric population. We focused on the difficulties of managing DOAC treatment in the presence of geriatric syndromes.
View Article and Find Full Text PDFComparing the Effect of DOAC-Stop and DOAC-Remove on Apixaban, Rivaroxaban and Dabigatran Prior to Thrombophilia and Lupus Testing.
Br J Biomed Sci
November 2024
Department of Haematology, Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom.
Background: Direct oral anticoagulants (DOACs) interfere with coagulation assays potentially leading to inaccurate results. This study determined the effectiveness of DOAC-stop® and DOAC-remove® in overcoming DOAC interference. It aimed to investigate the extent to which apixaban, rivaroxaban, and dabigatran had an effect on thrombophilia and lupus tests using normal plasma, as well as whether DOACs interfere with true-positive results by testing abnormal controls.
View Article and Find Full Text PDFChallenges of laboratory testing in patients suspected of antiphospholipid syndrome: practical implications for clinicians.
Pol Arch Intern Med
November 2024
Vascular Medicine Department and Reference Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Nancy University Hospital, Nancy, France
Article Synopsis
- The paper discusses the necessary laboratory tests for diagnosing antiphospholipid syndrome (APS) and emphasizes the importance of selecting the right patients to avoid misdiagnosis.
- It highlights the complexities of measuring lupus anticoagulant (LA) and details how to manage confounding factors, including anticoagulant therapy, using specific agents and assays, despite their limitations.
- The diagnosis relies on measuring three types of antiphospholipid antibodies (LA, anticardiolipin, and anti-β2-glycoprotein 1) to create antibody profiles, while suggesting that collaboration between pathologists and clinicians is crucial for accurate interpretation of results.
Challenges to Laboratory Monitoring of Direct Oral Anticoagulants.
Clin Appl Thromb Hemost
April 2024
Irvine Department of Pathology and Laboratory Medicine, University of California, Orange, CA, USA.
Direct oral anticoagulants (DOACs) exert anticoagulation effect by directly inhibiting Factor Xa (rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Though DOACs are characterized by fixed-dose prescribing and generally do not require routine laboratory drug-level monitoring (DLM), circumstances may arise where the DLM may aid in clinical decision-making, including DOAC dose adjustment, anticoagulant class change, or decisions to withhold or administer reversal agents. We review the current literature that describes high-risk patient groups in which DLM may be beneficial for improved patient anticoagulation management and stewardship.
View Article and Find Full Text PDFWhen Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.
J Am Coll Cardiol
January 2024
Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Internal Medicine, Radboud University Medical Center, Nijmege
For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease. DOACs do not provide a net benefit in conditions such as embolic stroke of undetermined source.
View Article and Find Full Text PDF